产品
编 号：F236498
分子式：C33H41ClN2O9
分子量：645.14
分子式：C33H41ClN2O9
分子量：645.14
产品类型
规格
价格
是否有货
结构图
CAS No: 189060-13-7
产品详情
生物活性：
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway. Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research.
体内研究：
Lapaquistat acetate (饮食补充；100 或 200 mg/kg；32 周) 降低血浆胆固醇和甘油三酯水平。它可以延缓冠状动脉粥样硬化的进展，并将冠状动脉粥样斑块从不稳定的、富含巨噬细胞/脂质积累的病变转变为 体内的稳定纤维肌肉病变。Animal Model:Male WHHLMI rabbits, aged 2 months
Dosage:100 or 200?mg/kg
Administration:Diet supplemented; 100 or 200?mg/kg; 32 weeks
Result:Increased collagen concentration and transformed coronary plaques into fibromuscular plaques.Suppressed the expression of MMP-1 and PAI-1 in the plaque and increased peripheral coenzyme Q10 levels.
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway. Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research.
体内研究：
Lapaquistat acetate (饮食补充；100 或 200 mg/kg；32 周) 降低血浆胆固醇和甘油三酯水平。它可以延缓冠状动脉粥样硬化的进展，并将冠状动脉粥样斑块从不稳定的、富含巨噬细胞/脂质积累的病变转变为 体内的稳定纤维肌肉病变。Animal Model:Male WHHLMI rabbits, aged 2 months
Dosage:100 or 200?mg/kg
Administration:Diet supplemented; 100 or 200?mg/kg; 32 weeks
Result:Increased collagen concentration and transformed coronary plaques into fibromuscular plaques.Suppressed the expression of MMP-1 and PAI-1 in the plaque and increased peripheral coenzyme Q10 levels.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备